GIP and type 2 diabetes mellitus: Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist weekly administered subcutaneously, has shown significant promise in the management of T2DM with efficient weight reduction (3).